Medication alone may not help everyone who suffers from depression.

The Mirai Depression Study is researching a digital mobile application that delivers an interactive, software-based intervention to see if it can help manage depression symptoms.

We are inviting you to take part in the Mirai Depression Study for adults with depression. There is no cost to participate. In addition, you may receive reimbursement for study-related expenses. No health insurance is required.

The Mirai Depression Study is evaluating the effectiveness of a digital therapeutic (Mirai Study App) in reducing depressive symptoms when used as an add-on therapy in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT).

To be eligible for this study, you must:

  • Be between the ages of 22 to 64
  • Be diagnosed with MDD and taking antidepressant medication
  • Continue to have symptoms of depression despite taking your prescribed antidepressant medication
  • Own a smartphone

Participants may receive reimbursement for study-related expenses in the Mirai Depression Study.
Participate
Participate
Participate

Sign Up

What happens if I sign up? We will use your information to see if you qualify for safe participation in the study. The study team will then contact you and you may have the opportunity to participate if qualified.


If you think you might like to participate in the Mirai Depression Study or would like more information, please enter your information below so we can see if you may qualify and can contact you about the study. Keep in mind that participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.

About Depression

Depression (or MDD) is a mood disorder that causes persistent feelings of sadness, hopelessness, and loss of interest. Depression can affect anybody at any age. Depression can be a result of a combination of genetic, biological, environmental, and psychological factors.1

It is estimated that depression affects one in every fifteen adults yearly, and one in every six people will experience depression at one point in their lives. There is a high degree of heritability (approximately 40%) when first-degree relatives (parents/children/siblings) have depression.2

MDD is a serious disorder that can have many associated complications, such as weight issues, substance abuse problems, anxiety or panic disorders, and suicidal feelings.

Symptoms of Depression:

  • Sadness, hopelessness, or emptiness
  • Sleep pattern changes
  • Feelings of worthlessness or guilt
  • Loss of interest
  • Anxiety or restlessness
  • Trouble thinking and concentrating

Many people with MDD struggle to find treatment that is completely effective. As a result, it’s important to research and study additional options for people with MDD.

The Mirai Study App is a digital mobile application that delivers an interactive, software-based intervention to see if it can help manage depression symptoms.

Frequently Asked Questions

What is a research study?

A research study (also called a clinical research study) is a medical study that helps to answer important questions about an investigational product – these may include how well an investigational product works for a certain condition. All products must be tested in clinical research studies before they can be approved and used in patients.

A research study is the process by which new and innovative medications, interventions and treatments are approved and brought to market, so people can live happier and healthier lives. Even over-the-counter medications, such as NSAIDs, you may have used to counteract a headache, have gone through the clinical research study process before it was available at your local pharmacy.

The purpose of this at-home study is to help researchers understand how using a digital therapeutic (a smartphone application) may help in managing the symptoms of depression. The study will compare the effectiveness of two digital therapeutics in reducing symptoms of depression, when used in addition to antidepressant medication.

The Mirai Study App is a digital mobile application that delivers an interactive, software-based intervention to see if it can help manage depression symptoms.

If you are eligible for this research study and decide to take part, you will be randomly assigned to download the Mirai Study App and use one of the two digital therapeutics for at least 6 weeks.

You will have visits with study staff by telephone and video conferencing throughout the study to monitor your signs and symptoms of depression.

You will receive all study-related procedures, assessments, and the digital therapeutics at no cost. All study related visits will be conducted remotely.

You will be in this study for approximately 13 weeks, which includes:

  • A 3-week screening period (Screening visit to Day 1)
  • A 6-week study treatment period (Day 1 to Week 6)
  • A 4-week extension period (Week 6 to Week 10)

Volunteers who qualify to take part in the study may receive reimbursement for study-related expenses. Please discuss this with the study team when they contact you.

There is no cost to participate in the Mirai Depression Study. If you decide to take part, you may receive reimbursement for study-related expenses.

The research team will be able to explain more about what the Mirai Depression Study will involve, and it is up to you to decide if you want to take part. Participation in this study is voluntary.

Vector

About the Mirai Depression Study

The Mirai Depression Study will enroll about 360 participants with depression (MDD) at approximately 35 research sites throughout the United States. Participation will last for approximately 13 weeks.

Participants do not have to pay for the digital therapeutics or any study-related procedures or assessments. In addition, you may receive reimbursement for study-related expenses.

There are other criteria that must be met in order for you to qualify for this study. You will be asked to answer a series of questions and may be further interviewed by a staff member to confirm your eligibility.

Who can take part in the Mirai Depression Study?

To be eligible for this study, you must:

  • Be between the ages of 22 to 64
  • Be diagnosed with MDD and taking antidepressant medication
  • Continue to have symptoms of depression despite taking your prescribed antidepressant medication
  • Own a smartphone

The Mirai Depression Study is evaluating the effectiveness of a digital therapeutic (Mirai Study App) in reducing depressive symptoms when used as an add-on therapy in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT).